[go: up one dir, main page]

MA50409A - Polythérapies pour le traitement du cancer - Google Patents

Polythérapies pour le traitement du cancer

Info

Publication number
MA50409A
MA50409A MA050409A MA50409A MA50409A MA 50409 A MA50409 A MA 50409A MA 050409 A MA050409 A MA 050409A MA 50409 A MA50409 A MA 50409A MA 50409 A MA50409 A MA 50409A
Authority
MA
Morocco
Prior art keywords
polytherapies
cancer
treatment
Prior art date
Application number
MA050409A
Other languages
English (en)
Inventor
Keith W Mikule
Kaiming Sun
Jing Yu Wang
Zebin Wang
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MA50409A publication Critical patent/MA50409A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA050409A 2017-09-30 2018-09-28 Polythérapies pour le traitement du cancer MA50409A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566398P 2017-09-30 2017-09-30
US201762578298P 2017-10-27 2017-10-27
US201862654024P 2018-04-06 2018-04-06

Publications (1)

Publication Number Publication Date
MA50409A true MA50409A (fr) 2020-08-26

Family

ID=65903287

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050409A MA50409A (fr) 2017-09-30 2018-09-28 Polythérapies pour le traitement du cancer

Country Status (13)

Country Link
US (1) US11661453B2 (fr)
EP (1) EP3697442A4 (fr)
JP (2) JP2020536066A (fr)
KR (1) KR20200086664A (fr)
CN (1) CN111372607A (fr)
AU (1) AU2018338901A1 (fr)
BR (1) BR112020006286A2 (fr)
CA (1) CA3076515A1 (fr)
IL (1) IL273395A (fr)
MA (1) MA50409A (fr)
MX (1) MX2020003770A (fr)
SG (1) SG11202002862RA (fr)
WO (1) WO2019067978A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155624B2 (en) * 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
WO2018183354A1 (fr) 2017-03-27 2018-10-04 Tesaro, Inc. Compositions de niraparib
AU2018258274C1 (en) 2017-04-24 2021-12-02 Tesaro, Inc. Methods of manufacturing of niraparib
TW202444417A (zh) * 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
EP3687505A1 (fr) 2017-09-26 2020-08-05 Tesaro Inc. Formulations de niraparib
EP3697442A4 (fr) 2017-09-30 2021-07-07 Tesaro, Inc. Polythérapies pour le traitement du cancer
MX2020003799A (es) 2017-10-06 2020-11-06 Tesaro Inc Terapias de combinacion y usos de las mismas.
CA3114465A1 (fr) * 2018-09-29 2020-04-02 Guangzhou Burning Rock Dx Co., Ltd. Procede base sur un sequencage de seconde generation pour la detection de la stabilite des microsatellites et de modifications du genome grace au plasma
EP4225383A4 (fr) * 2020-10-08 2024-12-11 Kumquat Biosciences Inc. Modulateurs de la proliferation cellulaire et leurs utilisations
US20240238283A1 (en) * 2021-05-18 2024-07-18 Onconic Therapeutics Inc. Parp inhibitor-resistant cancer therapeutic agent
CN113234160B (zh) * 2021-05-26 2022-05-27 广州爱思迈生物医药科技有限公司 一种抗pd-1抗体及其应用
WO2024259248A2 (fr) * 2023-06-15 2024-12-19 Memorial Sloan-Kettering Cancer Center Méthodes de traitement de patients cancéreux ayant un déficit de la recombinaison homologue sur la base d'empreintes de molécules longues pathognomoniques de voies de réparation de secours
KR20250087969A (ko) 2023-12-08 2025-06-17 주식회사 이앤지테크 팝업댓글 플랫폼을 활용한 소상공인 업소안내 증강현실 시스템 및 그 구동방법

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1333363C (fr) 1988-01-19 1994-12-06 Judah Folkman Inhibiteur de l'angiogenese contenant de la fumagilline
DE68915900T2 (de) 1988-09-01 1994-11-24 Childrens Medical Center Angiogenese hemmendes Mittel.
EP1537878B1 (fr) 2002-07-03 2010-09-22 Ono Pharmaceutical Co., Ltd. Compositions immunostimulantes
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
JP4611441B2 (ja) 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
RS51780B (sr) 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
EP2535354B1 (fr) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Anticorps dirigés contre le récepteur humain de mort programmée PD-1
NZ586125A (en) 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2009064444A2 (fr) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Traitement du cancer de l'utérus et du cancer de l'ovaire avec un inhibiteur parp utilisé seul ou en combinaison avec des antitumoraux
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
EP2237684A2 (fr) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonistes pour des systèmes peptidiques antimicrobiens
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
KR20110113648A (ko) 2009-02-04 2011-10-17 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제와 함께 성장인자 억제제를 사용한 폐암의 치료
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
WO2011153383A1 (fr) 2010-06-04 2011-12-08 Bipar Science, Inc. Procédés de traitement d'un cancer des ovaires récurrent et résistant au platine avec du 4-iodo-3-nitrobenzamide en combinaison avec un antimétabolite et un composé de platine.
EP2582847B1 (fr) 2010-06-18 2016-10-26 Myriad Genetics, Inc. Procédés et matériaux pour évaluer la perte d'hétérozygotie
EP2609216B1 (fr) 2010-08-24 2016-06-01 Dana-Farber Cancer Institute, Inc. Méthodes de prédiction d'une réponse anticancéreuse
CA2742342A1 (fr) 2011-02-12 2012-08-12 Baylor Research Institute Le statut a l'egard de l'expression de msh3 determine le degre de reponse des cellules cancereuses a un traitement chimiotherapeutique faisant intervenir des inhibiteurs de la parp et des medicaments a base de platine
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CA3126823C (fr) 2012-06-07 2023-04-04 Institut Curie Methodes de detection de l'inactivation de la voie de recombinaison homologue (brca1/2) dans les tumeurs humaines
WO2014088983A1 (fr) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Arylation n-2 régiosélective d'indazoles
WO2014088984A1 (fr) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Procédé de transamination biocatalytique
US9850542B2 (en) 2013-03-04 2017-12-26 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (HR) deficient cancer
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
PT2992017T (pt) * 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
EP3080292B1 (fr) 2013-12-09 2022-02-02 Institut Curie Procédé de détection de l'inactivation de la voie de recombination homologue (brca1/2) dans des tumeurs humaines
US20180163271A1 (en) 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
AU2015210886A1 (en) 2014-01-29 2016-09-01 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2015184145A1 (fr) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Utilisation de l'éribuline et des inhibiteurs de la poly(adp-ribose) polymérase (parp) en tant que que polythérapie pour le traitement du cancer
US20150344968A1 (en) 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
WO2016094391A1 (fr) 2014-12-08 2016-06-16 Myriad Genetics, Inc. Méthodes et matériaux permettant de prédire une réaction au niraparib
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
IL283006B2 (en) 2015-04-01 2023-10-01 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
KR20170138555A (ko) 2015-04-28 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
KR20180025888A (ko) 2015-06-08 2018-03-09 제넨테크, 인크. 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
CN107735104B (zh) 2015-06-25 2022-05-03 免疫医疗公司 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
WO2017031442A1 (fr) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Traitement combiné utilisant l'irinotécan liposomal et un inhibiteur de parp pour un traitement anticancéreux
CN108883115A (zh) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌
EP4071174A1 (fr) 2016-02-15 2022-10-12 AstraZeneca AB Procédés comprenant un dosage intermittent et fixe de cediranib
PT3478286T (pt) 2016-06-29 2024-01-31 Tesaro Inc Métodos de tratamento do cancro do ovário
US11202782B2 (en) * 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
US11155624B2 (en) 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
EP3689419A1 (fr) 2016-11-01 2020-08-05 AnaptysBio, Inc. Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
EP3606523A1 (fr) 2017-03-27 2020-02-12 Tesaro, Inc. Formulations de niraparib
WO2018183354A1 (fr) 2017-03-27 2018-10-04 Tesaro, Inc. Compositions de niraparib
AU2018258274C1 (en) 2017-04-24 2021-12-02 Tesaro, Inc. Methods of manufacturing of niraparib
KR102769634B1 (ko) 2017-04-27 2025-02-19 테사로, 인코포레이티드 림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
WO2019005762A1 (fr) 2017-06-26 2019-01-03 Abbvie Inc. Traitement du cancer du poumon non à petites cellules
EP3687505A1 (fr) 2017-09-26 2020-08-05 Tesaro Inc. Formulations de niraparib
EP3697442A4 (fr) 2017-09-30 2021-07-07 Tesaro, Inc. Polythérapies pour le traitement du cancer
MX2020003799A (es) 2017-10-06 2020-11-06 Tesaro Inc Terapias de combinacion y usos de las mismas.
WO2019133697A1 (fr) 2017-12-27 2019-07-04 Tesaro, Inc. Méthodes de traitement du cancer
EP3749352A1 (fr) 2018-02-05 2020-12-16 Tesaro Inc. Formulations pédiatriques de niraparib et procédés de traitement pédiatrique
EA201992594A1 (ru) 2018-03-26 2020-03-20 Тесаро, Инк. Комбинированные терапии для лечения рака
US11970530B2 (en) 2020-08-13 2024-04-30 Astrazeneca Ab Methods of treating homologous recombination deficient cancer

Also Published As

Publication number Publication date
US20200299387A1 (en) 2020-09-24
AU2018338901A1 (en) 2020-05-07
SG11202002862RA (en) 2020-04-29
BR112020006286A2 (pt) 2020-10-20
KR20200086664A (ko) 2020-07-17
EP3697442A1 (fr) 2020-08-26
IL273395A (en) 2020-05-31
MX2020003770A (es) 2020-07-29
CA3076515A1 (fr) 2019-04-04
EP3697442A4 (fr) 2021-07-07
JP2023076826A (ja) 2023-06-02
WO2019067978A1 (fr) 2019-04-04
US11661453B2 (en) 2023-05-30
JP2020536066A (ja) 2020-12-10
CN111372607A (zh) 2020-07-03

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
EP3368559A4 (fr) Compositions et méthodes pour le du traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
MA41555A (fr) Polythérapie pour le traitement du cancer
EP3359192A4 (fr) Polythérapie pour le traitement du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3331510A4 (fr) Thérapies combinatoires pour le traitement du cancer
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer